Oculis says its eye drops passed an early PhIII test. Researchers have to repeat it to win approval
A Swiss biotech focused on developing new eye treatments touted positive data from the first part of a multi-stage Phase III program Monday morning.
Oculis said its eye drop formulation of the corticosteroid dexamethasone achieved both primary endpoints in “Stage 1” of its Phase III trial in diabetic macular edema, showing statistically significant efficacy at six and 12 weeks in two different measurements. “Stage 2” of the Phase III study will examine the drug’s effect out to 12 months, which Oculis said is required for regulatory approval. That stage will begin in the second half of this year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.